左心室辅助器械治疗晚期心力衰竭:一个单中心的回顾性研究
Liangliang Liu1, Guiqing Liu2, Yang Zhao1
1Department of Cardiac and Great Vessel Surgery, Anhui Chest Hospital, Hefei, China.
Perfusion
|February 10, 2026
概括
中国的左心室辅助器件 (LVAD) 对晚期心力衰竭患者显示出有前途的结果. 这些设备显著改善心脏功能和患者的流动性,具有可接受的安全性.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 外科手术的结果
背景情况:
- 末期心力衰竭的管理正在通过左心室辅助器件 (LVAD) 发展.
- 在中国,为改善生活质量而采用LVAD的数量正在增加.
- 安胸部医院对LVAD植入的经验要求系统地呈现数据.
研究的目的:
- 介绍LVAD植入的临床数据和结果.
- 评估LVAD在中国患者中的有效性和安全性.
- 将手术前的基线与手术后3个月的结果进行比较.
主要方法:
- 连续28名LVAD患者的回顾性分析.
- 从2024年10月到2025年7月收集数据.
- 在植入后3个月,对左心室末端透析直径 (LVEDD),射出分数 (LVEF),NYHA类和6分钟步行距离 (6MWD) 的评估.
主要成果:
- 在所有28名患者中成功植入;平均年龄59.7岁.
- 3个月后观察到的显著改善:LVEDD下降,LVEF和6MWD增加 (p < 0.01).
- 所有幸存的患者都改善到NYHA类I-II;90天后的并发症包括中风,心律失常,功能衰竭和伤口愈合问题 (3.5-7%).
结论:
- 中国的LVAD在晚期心力衰竭中显示出良好的临床疗效.
- 应用LVAD显示了可接受的安全性.
- 在中国的背景下,LVAD作为终端心力衰竭的有效治疗策略.
更多相关视频
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
4.1K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
11.0K
相关概念视频
Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management
360
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360
